ReGen has indicated that the market value of Colostrinin orders it has received in the first five months of this year is approximately $2.2m, suggesting that the market for the product in the US, Canada and Australia is already annualising at some $5m/year. We believe the value of orders equates to revenues of c £220k, which provides reassurance that ReGen is on target to reach £500k revenue for 2008.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here